Media Release

Q2 FY18 Revenue at Rs. 66 crore, QoQ growth of 10%

Q2 FY18 EBITDA at Rs. 14 crore

Q2 FY18 EBITDA Margin at 22%

Q2 FY18 PAT at Rs. 9 crore, QoQ growth of over 23%

Q2 FY18 PAT Margin at 13%, QoQ increase of 190 bps

Q2 FY18 EPS at Rs. 3.79, QoQ growth of 23%

Mumbai, December 13, 2017: Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, today, announced its unaudited results for the quarter and half yearly ended September 30, 2017.

Our Company is pleased to announce its second quarter and half yearly ended unaudited financial results for the financial year ended 2017-18 and we have reported a strong growth in the quarter and also for the half year ended. This performance is on account of incremental demand of our products. Our focus remains towards further doing more backward integration within our product portfolio.

This performance is result of the growth momentum witnessed in the recent past and we still continue to witness huge traction in the demand for our products. Our Company is constantly making every effort to add new and new molecules.

At the same time our continuous focus on research and development, timely delivery, consistent and excellent quality has resulted in constant and increasing demand. The above mentioned focus areas have been the trademark and our biggest strength which has led to increased confidence of clients leading to a continuous flow of orders.

Q2 & H1 FY18 Financial Results Highlights

Q2 FY18 Vs. Q1 FY18 Highlights: -

- **Revenue** was at **Rs. 65.9 crore** in Q2 FY18 as against Rs. 60.0 crore in the Q1 FY18, growth of 10%
- **EBITDA** was at **Rs. 14.4 crore** in Q2 FY18 as against Rs. 16.6 crore in Q1 FY18
- **EBITDA Margin stood** at **22.3%** in Q2 FY18 as against 27.2% in Q1 FY18
- **Profit After Tax** was at **Rs. 8.7 crore** in Q2 FY18 as against Rs. 7.0 crore in Q1 FY18, **growth of 23%**
- **PAT Margin stood** at **13.4%** in Q2 FY18 as against 11.5% in Q1 FY18, an increase of **190 bps**
- **EPS Stood at Rs. 3.79** in Q2 FY18 as compared to **Rs. 3.08** in Q1 FY18**, growth of 23%**

H1 FY18 Highlights: -

- **Revenue** was at **Rs. 125.9 crore** in H1 FY18
- **EBITDA** was at **Rs. 31.0 crore** in H1 FY18
- **EBITDA Margin stood** at **24.7%** in H1 FY18
- **Profit After Tax** was at **Rs. 15.7 crore** in H1 FY18
- **PAT Margin stood** at **12.5%** in H1 FY18
- **EPS Stood at Rs. 6.87** in H1 FY18

Management Comments:

Commenting on the quarterly and half yearly unaudited results, Mr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

"This second quarter of financial year FY18, we have registered a revenue growth of 10% and our overall profit has also shown a tremendous increase of over 23%.

We are very happy that our consistent performance and focus on new and innovative products has been successfully helping us to bag new orders and grow our business. We have witnessed a lot of demand from different geographies for our products and remain focused on developing advanced catalyst chemistry for our molecules to enhance its productivity.

I thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."

About Lasa Supergenerics Limited:

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: www.lasalabs.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*